How advanced therapies are changing the CDMO landscape

Cell therapies continue to be blighted by CMC complexities and bottlenecks; Demand for viral vector production continues to outweigh supply. Increased investment in mRNA requires increased expertise to bring vaccines and therapies to market. This panel will assess how the CDMO sector has rallied to resolve these issues, what more can be done, and how new investments and companies entering the space are shaking up the dynamics in the sector.